Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06535698 · ClinicalTrials.gov registry record · NA
Evaluating the Effect of a Supplement on Symptoms of Hormonal Imbalance.
A NA study, sponsored by Perelel.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT06535698: Completed NA study, sponsored by Perelel.
NCT06535698 is a NA study that has completed, run by Perelel. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06535698, a NA study, has completed, sponsored by Perelel.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a virtual single-group trial lasting 12 weeks to evaluate the effects of Perelel Health's hormonal balance support on symptoms of hormonal imbalance and overall menstrual health.
Primary Outcome
Evaluation of the effect of Perelel Health hormonal balance support on symptoms of hormonal imbalance using a self-reported questionnaire.
Interventions
- DIETARY_SUPPLEMENT Perelel Health Hormonal Balance Support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2024-06-10 |
| Phase | NA |
What the finished NCT06535698 record still lists
NCT06535698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Perelel Health Hormonal Balance Support is the first listed.
NCT06535698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06535698 about?
NCT06535698 is a clinical study titled "Evaluating the Effect of a Supplement on Symptoms of Hormonal Imbalance.". This is a virtual single-group trial lasting 12 weeks to evaluate the effects of Perelel Health's hormonal balance support on symptoms of hormonal imbalance and overall menstrual health.
What is the current status of trial NCT06535698?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2024-02-19. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT06535698?
The interventions under investigation include: Perelel Health Hormonal Balance Support (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06535698?
This trial is sponsored by Perelel, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06535698's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI